Anavex Life Sciences Corp (AVXL)

[falconer66a]

Yes, just the questions I ponder.

Whether 2-73 will have therapeutic efficacy for conditions beyond AD and similar CNS disease remains to be determined. But the receptors are almost surely active in all neurons, and perhaps in other tissues, too.

Now, the following conjecture should not be regarded as anything to guide any future investments in AVXL. It's merely that, a conjecture, based upon the possibility that functional 2-73 receptors exist in many cell types, not just neurons. The conjecture is this: 2-73 may facilitate a diversity of normal cell functions, treating any number of geriatric conditions, where normal cell physiology no longer can work.

What might those conditions be, and what sorts of positive outcomes might occur? Utterly unknown. 2-73 has had (at least publicly) only the most limited clinical demonstration. Perhaps those who have worked with the substance in the lab, perhaps in animal models, have some experience and evidence for widespread treatment applications. Of course, none of us have heard a word of any of this. SEC rules prohibit such disclosure (as appropriate).

But, from my perspective, the crucial fulcrum point with 2-73 is this: it works like no other drug. There is nothing whatsoever to compare it to, to assess potential applications and treatments. The normalized cellular physiology that it facilitates in aged neurons (those with Alzheimer's dysfunctions) may well be therapeutic for any number of other diseases and conditions, not only in neurons but in other tissues (and diseases) as well.

I will follow the clinical development of this drug with great interest. It's unique, and may eventually have greatly expanded therapeutic applications.

But all of that is far in the future. Presently, we must be content with final clinical trials for AD, whenever they are announced.